Internship

Intern – Regulatory

Confirmed live in the last 24 hours

Cytokinetics

Cytokinetics

501-1,000 employees

Develops drugs for muscle function disorders

Biotechnology
Healthcare

Compensation Overview

$22 - $45Hourly

San Bruno, CA, USA

Paid internship at South San Francisco headquarters.

Category
Risk & Compliance
Legal & Compliance
Requirements
  • Currently enrolled undergraduate or graduate student or recent graduate with a major in science, engineering, or related field
  • Basic knowledge of healthcare industry and strong passion for biotech
  • Extremely organized, detail oriented and resourceful
  • Proficient in Microsoft programs including Outlook, Word, Excel, and PowerPoint
Responsibilities
  • Develop an understanding of the structure of and roles within a biopharmaceutical company and of the drug development process
  • Support the development of tools to enhance clinical process training and compliance
  • Assist with regulatory intelligence activities, including research, presentations, and development of communications tools
  • Develop regulatory skills required to assist in supporting clinical trial conduct and therapeutic program activities, including regulatory submissions and responses to health authority queries as needed
  • Support the maintenance of regulatory files and documentation to ensure compliance
  • Assist with development of new interdisciplinary processes
  • Gain cross-functional exposure to Regulatory CMC, Regulatory Advertising and Promotion, Regulatory Labeling, Regulatory Operations, Quality, and other functional areas
  • Assist with ongoing regulatory projects
  • Along with other Cytokinetics’ summer interns, showcase your work through a presentation to the organization

Cytokinetics focuses on developing medicines that improve muscle function for patients with cardiovascular and neuromuscular diseases. Their products are small molecule drugs designed to either enhance or inhibit muscle function, tailored to specific therapeutic needs. The company has a pipeline of drugs, including omecamtiv mecarbil and reldesemtiv, which are in various stages of clinical trials. Unlike many competitors, Cytokinetics emphasizes rigorous scientific research and has conducted over 50 clinical trials to ensure the effectiveness of its treatments. The goal is to bring new therapies to market that address the unmet needs of patients suffering from conditions like heart failure, ALS, and HCM.

Company Stage

IPO

Total Funding

$58.4M

Headquarters

South San Francisco, California

Founded

1998

Growth & Insights
Headcount

6 month growth

2%

1 year growth

1%

2 year growth

14%
Simplify Jobs

Simplify's Take

What believers are saying

  • Cytokinetics secured $575M funding from Royalty Pharma for R&D and commercial launch.
  • Positive Phase III results for aficamten in treating hypertrophic cardiomyopathy boost market potential.
  • Increased focus on personalized medicine aligns with Cytokinetics' individualized dosing strategies.

What critics are saying

  • Competition from Bristol-Myers Squibb's Camzyos may impact aficamten's market share.
  • Reliance on successful clinical trials poses risks if outcomes are negative.
  • Financial health depends on strategic funding, which may not always be guaranteed.

What makes Cytokinetics unique

  • Cytokinetics focuses on muscle activators and inhibitors for cardiovascular and neuromuscular diseases.
  • The company targets rare conditions like hypertrophic cardiomyopathy and amyotrophic lateral sclerosis.
  • Cytokinetics has a robust pipeline, including drugs like omecamtiv mecarbil and aficamten.

Help us improve and share your feedback! Did you find this helpful?